The role of cysteine proteinases and their inhibitors in the host-pathogen cross talk

Current Protein and Peptide Science

Volumn 13, Issue 8, 2012, Pages 767-775

  Kopitar Jerala, Nataša ^a  

^a JO EF STEFAN INSTITUTE   (Slovenia)

Author keywords

Bacteria; Immune response; Protease cysteine proteinase; Proteinase inhibitor; Virus

Indexed keywords

CATHEPSIN; CYSTATIN B; CYSTEINE; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; GAMMA INTERFERON; INFLAMMASOME; INTERLEUKIN 10; LEGUMAIN; NITRIC OXIDE; PAPAIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CELL CYCLE PROGRESSION; CORONAVIRUS; CYTOSOL; DENDRITIC CELL; DNA BINDING; FILOVIRUS; HOST PATHOGEN INTERACTION; IMMUNE RESPONSE; INFLAMMATION; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PARAMYXOVIRUS; PATHOGENESIS; REVIEW; STAPHYLOCOCCUS AUREUS; VIRUS INFECTIVITY;

ANIMALS; CATHEPSINS; CELLS; CYSTEINE PROTEASES; CYSTEINE PROTEINASE INHIBITORS; HOST-PATHOGEN INTERACTIONS; HUMANS;

EID: 84874827034     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/138920312804871102     Document Type: Review

References (140)

1. Janeway, C.A., Jr.; Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol., 2002, 20, 197-216.
2. Janeway, C.A. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harbor Symposia. Quantitat. Biol., 1989, 54, 1-13.
3. Akira, S.; Uematsu, S.; Takeuchi, O. Pathogen recognition and innate immunity. Cell, 2006, 124, 783-801.
4. Kawai, T.; Akira, S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity, 2011, 34, 637-650.
5. Akira, S.; Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol., 2004, 4, 499-511.
6. Medzhitov, R. Recognition of microorganisms and activation of the immune response. Nature, 2007, 449, 819-826.
7. Jin, M.S.; Lee, J.-O. Structures of the Toll-like receptor family and its ligand complexes. Immunity, 2008, 29, 182-191.
8. Kobe, B.; Kajava, A.V. The leucine-rich repeat as a protein recognition motif. Curr. Opin. Struct. Biol., 2001, 11, 725-732.
9. Jin, M.S.; Kim, S.E.; Heo, J.Y.; Lee, M.E.; Kim, H.M.; Paik, S.-G.; Lee, H.; Lee, J.-O. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell, 2007, 130, 1071-1082.
10. Kawai, T.; Akira, S. The role of pattern-recognition receptors in innate immunity: Update on toll-like receptors.Nat. Immunol., 2010, 11, 373-384.
11. Medzhitov, R.; Preston-Hurlburt, P.; Janeway, C.A. A human homologue of the Drosophila toll protein signals activation of adaptive immunity. Nature, 1997, 388, 394-397.
12. Kim, H.M.; Park, B.S.; Kim, J.-I.; Kim, S.E.; Lee, J.; Oh, S.C.; Enkhbayar, P.; Matsushima, N.; Lee, H.; Yoo, O.J.; Lee, J.-O. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist eritoran. Cell, 2007, 130, 906-917.
13. Beutler, B. TLR4 as the mammalian endotoxin sensor. Curr. Top. Microbiol. Immunol., 2002, 270, 109-120.
14. Poltorak, A.; He, X.; Smirnova, I.; Liu, M.Y.; Van Huffel, C.; Du, D.; Birdwell, D.; Alejos, E.; Silva, M.; Galanos, C.; Freudenberg, M.; Riccardi-Castagnoli, P.; Layton, B.; Beutier, B. Defective LPS signaling in C3H/Hej and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science, 1998, 282, 2085-2088.
15. Schwandner, R.; Dziarski, R.; Wesche, H.; Rothe, M.; Kirschning, C.J. Peptidoglycan-and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2. J. Biol. Chem., 1999, 274, 17406-17409.
16. Underhill, D.M.; Ozinsky, A.; Smith, K.D.; Aderem, A. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc. Nat. Acad. Sci., 1999, 96, 14459-14463.
17. Takeuchi, O.; Kawai, T.; Mühlradt, P.F.; Morr, M.; Radolf, J.D.; Zychlinsky, A.; Takeda, K.; Akira, S. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Intern. Immunol., 2001, 13, 933-940.
18. Latz, E.; Schoenemeyer, A.; Visintin, A.; Fitzgerald, K.A.; Monks, B.G.; Knetter, C.F.; Lien, E.; Nilsen, N.J.; Espevik, T.; Golenbock, D.T. Tlr9 signals after translocating from the er to cpg DNA in the lysosome. Nat. Immunol., 2004, 5, 190-198.
19. Tabeta, K.; Hoebe, K.; Janssen, E.M.; Du, X.; Georgel, P.; Crozat, K.; Mudd, S.; Mann, N.; Sovath, S.; Goode, J.; Shamel, L.; Herskovits, A.A.; Portnoy, D.A.; Cooke, M.; Tarantino, L.M.; Wiltshire, T.; Steinberg, B.E.; Grinstein, S.; Beutler, B. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat. Immunol., 2006, 7, 156-164.
20. Iwasaki, A.; Medzhitov, R. Regulation of adaptive immunity by the innate immune system. Science, 2010, 327, 291-295.
21. Rawlings, N.D.; Barrett, A.J.; Bateman, A. Merops: The database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res., 2012, 40, 15.
22. Barrett, A.J. Cellular proteolysis: An overview. Ann. NY. Acad. Sci., 1992, 674, 1-15.
23. Rawlings, N.D.; Barrett, A.J. Families of cysteine peptidases. Meth. Enzymol., 1994, 244, 461-486.
24. Barrett, A.J.; Kirschke, H. Cathepsin B, cathepsin H and cathepsin L. Meth. Enzymol., 1981, 80, 535-559.
25. Turk, V.; Stoka, V.; Vasiljeva, O.; Renko, M.; Sun, T.; Turk, B.; Turk, D. Cysteine cathepsins: From structure, function and regulation to new frontiers. Biochimica. Biophys. Acta -Pro. Proteom., 2012, 1824, 68-88.
26. Brix, K.; Dunkhorst, A.; Mayer, K.; Jordans, S. Cysteine cathepsins: Cellular roadmap to different functions. Biochimie, 2008, 90, 194-207.
27. Turk, V.; Turk, B.; Turk, D. Lysosomal cysteine proteases: Facts and opportunities. EMBO J., 2001, 20, 4629 -4633.
28. Reinheckel, T.; Deussing, J.; Roth, W.; Peters, C. Towards specific functions of lysosomal cysteine peptidases: Phenotypes of mice deficient for cathepsin B or cathepsin L. Biol. Chem., 2001, 382, 735-741.
29. Puente, X.S.; Sanchez, L.M.; Overall, C.M.; Lopez-Otin, C. Human and mouse proteases: A comparative genomic approach. Nat. Rev. Genet., 2003, 4, 544-558.
30. Santamaría, I.; Velasco, G.; Cazorla, M.; Fueyo, A.; Campo, E.; López-Otín, C. Cathepsin L2, a novel human cysteine proteinase produced by breast and colorectal carcinomas. Cancer Res., 1998, 58, 1624-1630.
31. Bromme, D.; Li, Z.; Barnes, M.; Mehler, E. Human cathepsin v functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization. Biochemistry, 1999, 38, 2377-2385.
32. Goulet, B.; Baruch, A.; Moon, N.S.; Poirier, M.; Sansregret, L.L.; Erickson, A.; Bogyo, M.; Nepveu, A. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in s phase and processes the CDP/Cux transcription factor. Mol. Cell, 2004, 14, 207-219.
33. Mehtani, S.; Gong, Q.; Panella, J.; Subbiah, S.; Peffley, D.M.; Frankfater, A. In vivo expression of an alternatively spliced human tumor message that encodes a truncated form of cathepsin B. J. Biol. Chem., 1998, 273, 13236-13244.
34. Maubach, G.; Lim, M.C.C.; Zhuo, L. Nuclear cathepsin fregulates activation markers in rat hepatic stellate cells. Mol. Biol. Cell, 2008, 19, 4238-4248.
35. Tedelind, S.; Poliakova, K.; Valeta, A.; Hunegnaw, R.; Yemanaberhan, E.L.; Heldin, N.E.; Kurebayashi, J.; Weber, E.; Kopitar-Jerala, N.; Turk, B.; Bogyo, M.; Brix, K. Nuclear cysteine cathepsin variants in thyroid carcinoma cells. Biol. Chem., 2010, 391(8):923-35.
36. Čeru, S.; Konjar, Š.; Maher, K.; Repnik, U.; Križaj, I.; Benčina, M.; Renko, M.; Nepveu, A.; Žerovnik, E.; Turk, B.; Kopitar-Jerala, N. Stefin b interacts with histones and cathepsin l in the nucleus. J. Biol. Chem., 2010, 285, 10078-10086.
37. Turk, V.; Stoka, V.; Turk, D. Cystatins: Biochemical and structural properties, and medical relevance. Front Biosci., 2008, 13, 5406 -5420.
38. Kopitar-Jerala, N. The role of cystatins in cells of the immune system. FEBS Lett., 2006, 580, 6295-6301.
39. Abrahamson, M.; Alvarez-Fernandez, M.; Nathanson, C.M. Cystatins. Biochem. Soc. Symp., 2003, 70, 179-199.
40. Lenarcic, B.; Bevec, T. Thyropins mdash new structurally related proteinase inhibitors. Biol. Chem., 1998, 379, 105-111.
41. Schick, C.; Pemberton, P.A.; Shi, G.-P.; Kamachi, Y.; Çataltepe, S.; Bartuski, A.J.; Gornstein, E.R.; Brömme, D.; Chapman, H.A.; Silverman, G.A. Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1:A kinetic analysis. Biochemistry, 1998, 37, 5258-5266.
42. Bevec, T.; Stoka, V.; Pungercic, G.; Dolenc, I.; Turk, V. Major histocompatibility complex class Ii-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L. J. Exp. Med., 1996, 183(4), 1331-1338.
43. Bevec, T.; Stoka, V.; Pungercic, G.; Cazzulo, J.J.; Turk, V. A fragment of the major histocompatibility complex class Iiassociated p41 invariant chain inhibits cruzipain, the major cysteine proteinase from trypanosoma cruzi. FEBS Lett., 1997, 401(2-3):259-261.
44. Guncar, G.; Pungercic, G.; Klemencic, I.; Turk, V.; Turk, D. Crystal structure of mhc class Ii-associated p41 ii fragment bound to cathepsin l reveals the structural basis for differentiation between cathepsins L and S. EMBO J., 1999, 18(4):793-803.
45. Barrett, A.J.; Fritz, H.; Grubb, A.; Isemura, S.; Jarvinen, M.; Katunuma, N.; Machleidt, W.; Muller-Esterl, W.; Sasaki, M.; Turk, V. Nomenclature and classification of the proteins homologous with the cysteine-proteinase inhibitor chicken cystatin. Biochem. J., 1986, 236(1), 312.
46. Bode, W.; Engh, R.; Musil, D.; Thiele, U.; Huber, R.; Karshikov, A.; Brzin, J.; Kos, J.; Turk, V. The 2.0 A x-ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases. Embo. J., 1988, 7, 2593-2599.
47. Stubbs, M.T.; Laber, B.; Bode, W.; Huber, R.; Jerala, R.; Lenarcic, B.; Turk, V. The refined 2.4 A X-ray crystal structure of recombinant human stefin B in complex with the cysteine proteinase papain: A novel type of proteinase inhibitor interaction. Embo. J., 1990, 9, 1939-1947.
48. Salvesen, G.; Parkes, C.; Abrahamson, M.; Grubb, A.; Barrett, A.J. Human low-mr kininogen contains three copies of a cystatin sequence that are divergent in structure and in inhibitory activity for cysteine proteinases. Biochem. J., 1986, 234, 429-434.
49. Ohkubo, I.; Kurachi, K.; Takasawa, T.; Shiokawa, H.; Sasaki, M. Isolation of a human cDNA for alpha 2-thiol proteinase inhibitor and its identity with low molecular weight kininogen. Biochemistry, 1984, 23, 5691-5697.
50. Silverman, G.A.; Bird, P.I.; Carrell, R.W.; Church, F.C.; Coughlin, P.B.; Gettins, P.G.W.; Irving, J.A.; Lomas, D.A.; Luke, C.J.; Moyer, R.W.; Pemberton, P.A.; Remold-O'Donnell, E.; Salvesen, G.S.; Travis, J.; Whisstock, J.C. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. J. Biol. Chem., 2001, 276, 33293-33296.
51. Huntington, J.A.; Read, R.J.; Carrell, R.W. Structure of a serpinprotease complex shows inhibition by deformation. Nature, 2000, 407, 923-926.
52. Al-Khunaizi, M. The serpin SQN-5 is a dual mechanistic-class inhibitor of serine and cysteine proteinases. Biochemistry, 2002, 41, 3189-3199.
53. Annand, R.R.; Dahlen, J.R.; Sprecher, C.A.; De Dreu, P.; Foster, D.C.; Mankovich, J.A.; Talanian, R.V.; Kisiel, W.; Giegel, D.A. Caspase-1 (interleukin-1beta-converting enzyme) is inhibited by the human serpin analogue proteinase inhibitor 9. Biochem. J., 1999, 342, 655-665.
54. Komiyama, T.; Ray, C.A.; Pickup, D.J.; Howard, A.D.; Thornberry, N.A.; Peterson, E.P.; Salvesen, G. Inhibition of interleukin-1 beta converting enzyme by the cowpox virus serpin CrmA. An example of cross-class inhibition. J. Biol. Chem., 1994, 269, 19331-19337.
55. Liu, N.; Raja, S.M.; Zazzeroni, F.; Metkar, S.S.; Shah, R.; Zhang, M.; Wang, Y.; Bromme, D.; Russin, W.A.; Lee, J.C.; Peter, M.E.; Froelich, C.J.; Franzoso, G.; Ashton-Rickardt, P.G. Nf-[kappa]b protects from the lysosomal pathway of cell death. EMBO J., 2003, 22, 5313-5322.
56. Gordon, S.; Taylor, P.R. Monocyte and macrophage heterogeneity. Nature Rev. Immunol., 2005, 5, 953-964.
57. Martinez, F.O.; Sica, A.; Mantovani, A.; Locati, M. Macrophage activation and polarization. Front. Biosci., 2008, 13, 453-461.
58. Hajishengallis, G.; Lambris, J.D. Microbial manipulation of receptor crosstalk in innate immunity. Nat. Rev. Immunol., 2011, 11, 187-200.
59. Murray, P.J.; Wynn, T.A. Obstacles and opportunities for understanding macrophage polarization. J. Leukoc. Biol., 2011, 89, 557-563.
60. Geissmann, F.; Jung, S.; Littman, D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity, 2003, 19, 71-82.
61. Sutterwala, F.S.; Noel, G.J.; Clynes, R.; Mosser, D.M. Selective suppression of interleukin-12 induction after macrophage receptor ligation. J. Exp. Med., 1997, 185, 1977-1985.
62. Saraiva, M.; O'Garra, A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol., 2010, 10, 170-181.
63. Verdot, L.; Lalmanach, G.; Vercruysse, V.; Hartmann, S.; Lucius, R.; Hoebeke, J.; Gauthier, F.; Vray, B. Cystatins up-regulate nitric oxide release from interferon-activated mouse peritoneal macrophages. J. Biol. Chem., 1996, 271, 28077-28081.
64. Verdot, L.; Lalmanach, G.; Vercruysse, V.; Hoebeke, J.; Gauthier, F.; Vray, B. Chicken cystatin stimulates nitric oxide release from interferon-γactivated mouse peritoneal macrophages via cytokine synthesis. Euro. J. Biochem., 1999, 266, 1111-1117.
65. Frendéus, K.H.; Wallin, H.; Janciauskiene, S.; Abrahamson, M. Macrophage responses to interferon-are dependent on cystatin C levels. Intern. J. Biochem. amp; Cell Biol., 2009, 41, 2262-2269.
66. Hsing, L.C.; Rudensky, A.Y. The lysosomal cysteine proteases in MHC class Ii antigen presentation. Immunol. Rev., 2005, 207, 229-241.
67. Bird, P.I.; Trapani, J.A.; Villadangos, J.A. Endolysosomal proteases and their inhibitors in immunity. Nat. Rev. Immunol., 2009, 9, 871-882.
68. Hamerman, J.A.; Hayashi, F.; Schroeder, L.A.; Gygi, S.P.; Haas, A.L.; Hampson, L.; Coughlin, P.; Aebersold, R.; Aderem, A. Serpin 2a is induced in activated macrophages and conjugates to a ubiquitin homolog. J. Immunol., 2002, 168, 2415-2423.
69. Beers, C.; Honey, K.; Fink, S.; Forbush, K.; Rudensky, A. Differential regulation of cathepsin S and cathepsin L in interferon -treated macrophages. J. Exp. Med., 2003, 197, 169-179.
70. Colbert, J.D.; Matthews, S.P.; Kos, J.; Watts, C. Internalization of exogenous cystatin F supresses cysteine proteases and induces the accumulation of single-chain cathepsin L by multiple mechanisms. J. Biol. Chem., 2011, 286, 42082-42090.
71. Konjar S., Yin, F.; Bogyo, M.; Turk, B.; Kopitar-Jerala, N. Increased nucleolar localization of Spia3g in classically but not alternatively activated macrophages. FEBS Lett., 2010, 584, 2201-2206.
72. Schroder, K.; Tschopp, J. The inflammasomes. Cell, 2010, 140, 821-832.
73. Pang, I.K.; Iwasaki, A. Control of antiviral immunity by pattern recognition and the microbiome. Immunol Rev., 2012, 245(1),209-226. doi: 10.1111/j.1600-065X.2011.01073.x.
74. Halle, A.; Hornung, V.; Petzold, G.C.; Stewart, C.R.; Monks, B.G.; Reinheckel, T.; Fitzgerald, K.A.; Latz, E.; Moore, K.J.; Golenbock, D.T. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol., 2008, 9(8), 857-865.
75. Hornung, V.; Bauernfeind, F.; Halle, A.; Samstad, E.O.; Kono, H.; Rock, K.L.; Fitzgerald, K.A.; Latz, E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol.2008 9(8), 847-856.
76. Kono, H.; Chen, C.J.; Ontiveros, F.; Rock, K.L. Uric acid promotes an acute inflammatory response to sterile cell death in mice. J. Clin. Invest., 2010, 120(6), 1939-1949. doi: 10.1172/JCI40124.
77. Masters, S.L.; O'Neill, L.A. Disease-associated amyloid and misfolded protein aggregates activate the inflammasome. Trends Mol. Med., 2011, 17(5), 276-282.
78. Duewell, P.; Kono, H.; Rayner, K.J.; Sirois, C.M.; Vladimer, G.; Bauernfeind, F.G.; Abela, G.S.; Franchi, L.; Nunez, G.; Schnurr, M.; Espevik, T.; Lien, E.; Fitzgerald, K.A.; Rock, K.L.; Moore, K.J.; Wright, S.D.; Hornung, V.; Latz, E. Nlrp3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature, 2010, 464(7293):1357-61.
79. Chen, C.-C.; Tsai, S.-H.; Lu, C.-C.; Hu, S.-T.; Wu, T.-S.; Huang, T.-T.; Saïd-Sadier, N.; Ojcius, D.M.; Lai, H.-C. Activation of an NLRP3 inflammasome restricts Mycobacterium kansasii infection. PLoS ONE, 2012, 7, e36292.
80. Liu, K.; Nussenzweig, M.C. Origin and development of dendritic cells. Immunol. Rev., 2010, 234, 45-54.
81. Naik, S.H. Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. Nature Immunol., 2007, 8, 1217-1226.
82. Sauter, B.; Albert, M.L.; Francisco, L.; Larsson, M.; Somersan, S.; Bhardwaj, N. Consequences of cell death. J. Exp. Med., 2000, 191, 423-434.
83. Hartmann, G.; Weiner, G.J.; Krieg, A.M. Cpg DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proc. Nat. Acad. Sci., 1999, 96, 9305-9310.
84. Joffre, O.; Nolte, M.A.; Spörri, R.; Sousa, C.R.E. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity.Immunol. Rev., 2009, 227, 234-247.
85. Cella, M.; Engering, A.; Pinet, V.; Pieters, J.; Lanzavecchia, A. Inflammatory stimuli induce accumulation of MHC class Ii complexes on dendritic cells. Nature, 1997, 388, 782-787.
86. Swiecki, M.; Colonna, M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol. Rev., 2010, 234, 142-162.
87. Delamarre, L.; Pack, M.; Chang, H.; Mellman, I.; Trombetta, E.S. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science, 2005, 307, 1630-1634.
88. McCurley, N.; Mellman, I. Monocyte-derived dendritic cells exhibit increased levels of lysosomal proteolysis as compared to other human dendritic cell populations. PLoS ONE, 2010, 5, e11949.
89. Shi, G.P.; Villadangos, J.A.; Dranoff, G.; Small, C.; Gu, L.; Haley, K.J.; Riese, R.; Ploegh, H.L.; Chapman, H.A. Cathepsin S required for normal MHC class Ii peptide loading and germinal center development. Immunity, 1999, 10, 197-206.
90. Nakagawa, T.; Roth, W.; Wong, P.; Nelson, A.; Farr, A.; Deussing, J.; Villadangos, J.A.; Ploegh, H.; Peters, C.; Rudensky, A.Y. Cathepsin L: Critical role in II degradation and CD4 T cell selection in the thymus. Science, 1998, 280, 450-453.
91. Nakagawa, T.Y.; Brissette, W.H.; Lira, P.D.; Griffiths, R.J.; Petrushova, N.; Stock, J.; McNeish, J.D.; Eastman, S.E.; Howard, E.D.; Clarke, S.R.; Rosloniec, E.F.; Elliott, E.A.; Rudensky, A.Y. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity, 1999, 10, 207-217.
92. Tolosa, E.; Li, W.; Yasuda, Y.; Wienhold, W.; Denzin, L.K.; Lautwein, A.; Driessen, C.; Schnorrer, P.; Weber, E.; Stevanovic, S.; Kurek, R.; Melms, A.; Bromme, D. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. J. Clin. Invest., 2003, 112, 517-526.
93. Pierre, P.; Mellman, I. Developmental regulation of invariant chain proteolysis controls MHC class Ii trafficking in mouse dendritic cells. Cell, 1998, 93, 1135-1145.
94. El-Sukkari, D.; Wilson, N.S.; Hakansson, K.; Steptoe, R.J.; Grubb, A.; Shortman, K.; Villadangos, J.A. The protease inhibitor cystatin C is differentially expressed among dendritic cell populations, but does not control antigen presentation. J. Immunol., 2003, 171, 5003-5011.
95. Cella, M.; Jarrossay, D.; Facchetti, F.; Alebardi, O.; Nakajima, H.; Lanzavecchia, A.; Colonna, M. Plasmacytoid monocytes migrate to interferon. Nat. Med., 1999, 5, 919-923.
96. Brinkmann, M.M. The interaction between the ER membrane protein UNC93b and TLR3, 7, and 9 is crucial for TLR signaling. J. Cell Biol., 2007, 177, 265-275.
97. Fukui, R. Unc93b1 biases toll-like receptor responses to nucleic acid in dendritic cells toward DNA-but against RNA-sensing. J. Exp. Med., 2009, 206, 1339-1350.
98. Asagiri, M.; Hirai, T.; Kunigami, T.; Kamano, S.; Gober, H.J.; Okamoto, K.; Nishikawa, K.; Latz, E.; Golenbock, D.T.; Aoki, K.; Ohya, K.; Imai, Y.; Morishita, Y.; Miyazono, K.; Kato, S.; Saftig, P.; Takayanagi, H. Cathepsin K-dependent Toll-like receptor 9 signaling revealed in experimental arthritis. Science, 2008, 319, 624-627.
99. Ewald, S.E.; Engel, A.; Lee, J.; Wang, M.; Bogyo, M.; Barton, G.M. Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase. J. Exp. Med., 2011, 208, 643-651.
100. Ewald, S.E.; Lee, B.L.; Lau, L.; Wickliffe, K.E.; Shi, G.P.; Chapman, H.A.; Barton, G.M. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature, 2008, 456, 658-662.
101. Park, B.; Brinkmann, M.M.; Spooner, E.; Lee, C.C.; Kim, Y.M.; Ploegh, H.L. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat. Immunol., 2008, 9, 1407-1414.
102. Ohbayashi, T.; Irie, A.; Murakami, Y.; Nowak, M.; Potempa, J.; Nishimura, Y.; Shinohara, M.; Imamura, T. Degradation of fibrinogen and collagen by staphopains, cysteine proteases released from Staphylococcus aureus. Microbiology, 2011, 157, 786-792.
103. Zabel, B.A.; Silverio, A.M.; Butcher, E.C. Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood. J. Immunol., 2005, 174, 244-251.
104. Zabel, B.A.; Allen, S.J.; Kulig, P.; Allen, J.A.; Cichy, J.; Handel, T.M.; Butcher, E.C. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J. Biol. Chem., 2005, 280, 34661-34666.
105. Kulig, P.; Kantyka, T.; Zabel, B.A.; Banas, M.; Chyra, A.; Stefanska, A.; Tu, H.; Allen, S.J.; Handel, T.M.; Kozik, A.; Potempa, J.; Butcher, E.C.; Cichy, J. Regulation of chemerin chemoattractant and antibacterial activity by human cysteine cathepsins. J. Immunol., 2011, 187, 1403-1410.
106. Kulig, P.; Zabel, B.A.; Dubin, G.; Allen, S.J.; Ohyama, T.; Potempa, J.; Handel, T.M.; Butcher, E.C.; Cichy, J. Staphylococcus aureus-derived staphopain B, a potent cysteine protease activator of plasma chemerin. J. Immunol., 2007, 178, 3713-3720.
107. Kordis, D.; Turk, V. Phylogenomic analysis of the cystatin superfamily in eukaryotes and prokaryotes. BMC Evol. Biol., 2009, 9, 266.
108. von Pawel-Rammingen, U.; Björck, L. Ides and speb: Immunoglobulin-degrading cysteine proteinases of Streptococcus pyogenes. Curr. Opin. Microbiol., 2003, 6, 50-55.
109. Vincents, B.; von Pawel-Rammingen, U.; Björck, L.; Abrahamson, M. Enzymatic characterization of the Streptococcal endopeptidase, ides, reveals that it is a cysteine protease with strict specificity for igg cleavage due to exosite binding. Biochemistry, 2004, 43, 15540-15549.
110. Vincents, B.; Vindebro, R.; Abrahamson, M.; von Pawel-Rammingen, U. The human protease inhibitor cystatin C is an activating cofactor for the Streptococcal cysteine protease ides. Chem. Biol., 2008, 15, 960-968.
111. Thomas, V.; Samanta, S.; Fikrig, E. Anaplasma phagocytophilum increases cathepsin L activity, thereby globally influencing neutrophil function. Infect. Immun., 2008, 76, 4905-4912.
112. Grove, J.; Marsh, M. The cell biology of receptor-mediated virus entry. J. Cell Biol., 2011, 195, 1071-1082.
113. Skehel, J.J.; Bayley, P.M.; Brown, E.B.; Martin, S.R.; Waterfield, M.D.; White, J.M.; Wilson, I.A.; Wiley, D.C. Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. Proc. Natl. Acad. Sci. USA., 1982, 79, 968-972.
114. Wilson, I.A.; Skehel, J.J.; Wiley, D.C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature, 1981, 289, 366-373.
115. Baker, K.A.; Dutch, R.E.; Lamb, R.A.; Jardetzky, T.S. Structural basis for paramyxovirus-mediated membrane fusion. Mol. Cell, 1999, 3, 309-319.
116. Chan, D.C.; Fass, D.; Berger, J.M.; Kim, P.S. Core structure of gp41 from the hiv envelope glycoprotein. Cell, 1997, 89, 263-273.
117. Weissenhorn, W.; Dessen, A.; Harrison, S.C.; Skehel, J.J.; Wiley, D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature, 1997, 387, 426-430.
118. Chandran, K.; Sullivan, N.J.; Felbor, U.; Whelan, S.P.; Cunningham, J.M. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science, 2005, 308, 1643-1645
119. MacNeil, A.; Rollin, P.E. Ebola and Marburg hemorrhagic fevers: Neglected tropical diseases? PLoS Negl Trop Dis, 2012, 6, 26.
120. Lee, J.E.; Fusco, M.L.; Hessell, A.J.; Oswald, W.B.; Burton, D.R.; Saphire, E.O. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature, 2008, 454, 177-182.
121. Lee, J.E.; Saphire, E.O. Ebolavirus glycoprotein structure and mechanism of entry. Future Virol., 2009, 4, 621-635.
122. Hood, C.L. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: Implications for viral entry and immunogenicity. J. Virol., 2010, 84, 2972-2982.
123. Schornberg, K.; Matsuyama, S.; Kabsch, K.; Delos, S.; Bouton, A.; White, J. Role of endosomal cathepsins in entry mediated by the ebola virus glycoprotein. J. Virol., 2006, 80, 4174-4178.
124. Wong, A.C.; Sandesara, R.G.; Mulherkar, N.; Whelan, S.P.; Chandran, K. A forward genetic strategy reveals destabilizing mutations in the Ebola virus glycoprotein that alter its protease dependence during cell entry. J. Virol., 2010, 84, 163-175.
125. Cote, M.; Misasi, J.; Ren, T.; Bruchez, A.; Lee, K.; Chandran, K.; Filone, C.M.; Hensley, L.; Li, Q.; Ory, D.; Cunningham, J. Small molecule inhibitors reveal Niemann-Pick C1 is essential for ebola virus infection. Nature, 2011, 477, 344-348.
126. Carette, J.E.; Raaben, M.; Wong, A.C.; Herbert, A.S.; Obernosterer, G.; Mulherkar, N.; Kuehne, A.I.; Kranzusch, P.J.; Griffin, A.M.; Ruthel, G.; Dal Cin, P.; Dye, J.M.; Whelan, S.P.; Chandran, K.; Brummelkamp, T.R. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature, 2011, 477, 340-343
127. Misasi, J.; Chandran, K.; Yang, J.Y.; Considine, B.; Filone, C.M.; Cote, M.; Sullivan, N.; Fabozzi, G.; Hensley, L.; Cunningham, J. Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences. J. Virol., 2012, 86, 3284-3292.
128. Feldmann, H.; Geisbert, T.W. Ebola haemorrhagic fever. Lancet, 2011, 377, 849-862.
129. Qiu, X.; Audet, J.; Wong, G.; Pillet, S.; Bello, A.; Cabral, T.; Strong, J.E.; Plummer, F.; Corbett, C.R.; Alimonti, J.B.; Kobinger, G.P. Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Translation. Med., 2012, 4, 138-181.
130. Kawase, M.; Shirato, K.; Matsuyama, S.; Taguchi, F. Proteasemediated entry via the endosome of human Coronavirus 229E. J. Virol., 2009, 83, 712-721.
131. Simmons, G.; Gosalia, D.N.; Rennekamp, A.J.; Reeves, J.D.; Diamond, S.L.; Bates, P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Nat. Acad. Sci. USA., 2005, 102, 11876-11881.
132. Belouzard, S.; Chu, V.C.; Whittaker, G.R. Activation of the sars coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc. Natl. Acad. Sci. USA, 2009, 106, 5871-5876.
133. Huang, I.C.; Bosch, B.J.; Li, F.; Li, W.; Lee, K.H.; Ghiran, S.; Vasilieva, N.; Dermody, T.S.; Harrison, S.C.; Dormitzer, P.R.; Farzan, M.; Rottier, P.J.M.; Choe, H. Sars coronavirus, but not human Coronavirus Nl63, Utilizes Cathepsin L to Infect ACE2-expressing cells. J. Biol. Chem., 2006, 281, 3198-3203.
134. Guan, Y.; Zheng, B.J.; He, Y.Q.; Liu, X.L.; Zhuang, Z.X.; Cheung, C.L.; Luo, S.W.; Li, P.H.; Zhang, L.J.; Guan, Y.J.; Butt, K.M.; Wong, K.L.; Chan, K.W.; Lim, W.; Shortridge, K.F.; Yuen, K.Y.; Peiris, J.S.M.; Poon, L.L.M. Isolation and characterization of Cysteine Proteinases and Inhibitors in Host Defense Current Protein and Peptide Science, 2012, Vol. 13, No. 8775 viruses related to the SARS coronavirus from animals in southern China. Science, 2003, 302, 276-278.
135. Miyoshi-Akiyama, T.; Ishida, I.; Fukushi, M.; Yamaguchi, K.; Matsuoka, Y.; Ishihara, T.; Tsukahara, M.; Hatakeyama, S.; Itoh, N.; Morisawa, A.; Yoshinaka, Y.; Yamamoto, N.; Lianfeng, Z.; Chuan, Q.; Kirikae, T.; Sasazuki, T. Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) Coronavirus S Protein Neutralizes the Virus in a Rhesus Macaque SARS Model. J. Infect. Dis., 2011, 203, 1574-1581.
136. Chang, A.; Dutch, R.E. Paramyxovirus fusion and entry: Multiple paths to a common end. Viruses, 2012, 4, 613-636.
137. Diederich, S.; Sauerhering, L.; Weis, M.; Altmeppen, H.; Schaschke, N.; Reinheckel, T.; Erbar, S.; Maisner, A. Activation of the Nipah virus fusion protein in MDCK cells is mediated by cathepsin B within the endosome-recycling compartment. J. Virol., 2012, 86, 3736-3745
138. Lee, P.W.K.; Hayes, E.C.; Joklik, W.K. Protein 1 is the reovirus cell attachment protein. Virology, 1981, 108, 156-163.
139. Borsa, J.; Sargent, M.D.; Lievaart, P.A.; Copps, T.P. Reovirus: Evidence for a second step in the intracellular uncoating and transcriptase activation process. Virology, 1981, 111, 191-200.
140. Johnson, E.M.; Doyle, J.D.; Wetzel, J.D.; McClung, R.P.; Katunuma, N.; Chappell, J.D.; Washington, M.K.; Dermody, T.S. Genetic and pharmacologic alteration of cathepsin expression influences reovirus pathogenesis. J. Virol., 2009, 83, 9630-9640.